These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

466 related items for PubMed ID: 12163626

  • 1. PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease.
    Kostakoglu L, Coleman M, Leonard JP, Kuji I, Zoe H, Goldsmith SJ.
    J Nucl Med; 2002 Aug; 43(8):1018-27. PubMed ID: 12163626
    [Abstract] [Full Text] [Related]

  • 2. Prognostic value of PET using 18F-FDG in Hodgkin's disease for posttreatment evaluation.
    Guay C, Lépine M, Verreault J, Bénard F.
    J Nucl Med; 2003 Aug; 44(8):1225-31. PubMed ID: 12902411
    [Abstract] [Full Text] [Related]

  • 3. Predictive value of (18)F-FDG hybrid PET/CT for the clinical outcome in patients with non-Hodgkin's lymphoma prior to and after autologous stem cell transplantation.
    Qiao W, Zhao J, Wang C, Wang T, Xing Y.
    Hematology; 2010 Feb; 15(1):21-7. PubMed ID: 20132658
    [Abstract] [Full Text] [Related]

  • 4. Persistent tumor 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma.
    Jerusalem G, Beguin Y, Fassotte MF, Najjar F, Paulus P, Rigo P, Fillet G.
    Haematologica; 2000 Jun; 85(6):613-8. PubMed ID: 10870118
    [Abstract] [Full Text] [Related]

  • 5. Early therapy monitoring with FDG-PET in aggressive non-Hodgkin's lymphoma and Hodgkin's lymphoma.
    Torizuka T, Nakamura F, Kanno T, Futatsubashi M, Yoshikawa E, Okada H, Kobayashi M, Ouchi Y.
    Eur J Nucl Med Mol Imaging; 2004 Jan; 31(1):22-8. PubMed ID: 14574514
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Early restaging positron emission tomography with ( 18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma.
    Spaepen K, Stroobants S, Dupont P, Vandenberghe P, Thomas J, de Groot T, Balzarini J, De Wolf-Peeters C, Mortelmans L, Verhoef G.
    Ann Oncol; 2002 Sep; 13(9):1356-63. PubMed ID: 12196360
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation.
    Becherer A, Mitterbauer M, Jaeger U, Kalhs P, Greinix HT, Karanikas G, Pötzi C, Raderer M, Dudczak R, Kletter K.
    Leukemia; 2002 Feb; 16(2):260-7. PubMed ID: 11840293
    [Abstract] [Full Text] [Related]

  • 13. FDG-PET/CT predicts outcome in patients with aggressive non-Hodgkin's lymphoma and Hodgkin's disease.
    Querellou S, Valette F, Bodet-Milin C, Oudoux A, Carlier T, Harousseau JL, Chatal JF, Couturier O.
    Ann Hematol; 2006 Nov; 85(11):759-67. PubMed ID: 16871391
    [Abstract] [Full Text] [Related]

  • 14. Computed tomography and 18F-FDG positron emission tomography for therapy control of Hodgkin's and non-Hodgkin's lymphoma patients: when do we really need FDG-PET?
    Reinhardt MJ, Herkel C, Altehoefer C, Finke J, Moser E.
    Ann Oncol; 2005 Sep; 16(9):1524-9. PubMed ID: 15946979
    [Abstract] [Full Text] [Related]

  • 15. Prognostic significance of positron emission tomography using fluorine-18-fluorodeoxyglucose in patients treated for malignant lymphoma.
    Cremerius U, Fabry U, Neuerburg J, Zimny M, Bares R, Osieka R, Büll U.
    Nuklearmedizin; 2001 Feb; 40(1):23-30. PubMed ID: 11373935
    [Abstract] [Full Text] [Related]

  • 16. FDG-PET in the detection of bone marrow disease in Hodgkin's disease and aggressive non-Hodgkin's lymphoma and its impact on clinical management.
    Pelosi E, Penna D, Deandreis D, Chiappella A, Skanjeti A, Vitolo U, Bisi G.
    Q J Nucl Med Mol Imaging; 2008 Mar; 52(1):9-16. PubMed ID: 18235420
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. The prognostic value of 18F-FDG PET-CT in the management of Hodgkin's lymphoma: preliminary results of a prospective study.
    Paolini R, Rampin L, Rodella E, Ramazzina E, Banti E, Al-Nahhas A, Rubello D.
    Nucl Med Rev Cent East Eur; 2007 Mar; 10(2):87-90. PubMed ID: 18228212
    [Abstract] [Full Text] [Related]

  • 20. 18F-FDG PET for posttherapy assessment of Hodgkin's disease and aggressive Non-Hodgkin's lymphoma: a systematic review.
    Terasawa T, Nihashi T, Hotta T, Nagai H.
    J Nucl Med; 2008 Jan; 49(1):13-21. PubMed ID: 18077527
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.